Remove .Net Remove Document Remove Pricing Remove Technical Review
article thumbnail

Are Business Plans Still Necessary?

Both Sides of the Table

So, definition: when I talk about a business plan I’m not talking about a 40-page Word document outlining your market approach. Usually in a tech / software startup 70-80% of your costs will be people. ’ Our Net Income will be $40 million.&#. 66% Net Operating Margins? Or do you need to raise prices?

Web 2.0 334
article thumbnail

10 Realities Today Cause Startups To Bypass An IPO

Startup Professionals Musings

Smart entrepreneurs are just now starting to look at this option again, due to its unpredictability and the challenges of running a public company. Too many startups have experienced early financial losses and technical glitches, like Uber and the Zynga IPO a while back, which antagonized individual investors and startup executives as well.

Startup 84
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

10 Negatives That Still Make Going Public A High Risk

Startup Professionals Musings

Smart entrepreneurs are just now starting to look at this option again, due to its unpredictability and the challenges of running a public company. Yet they still see warning lights in many geographies around the world, due to political uncertainties. The M&A alternative looks simple by comparison.

Startup 87
article thumbnail

Taking Your Startup Public Is Fraught With Negatives

Startup Professionals Musings

Smart entrepreneurs now avoid this option like the plague, due to its unpredictability and the challenges of running a public company. Because public shareholders usually take the short-term view, they want to see constant rises in the stock''s price so they can sell their shares for a profit. Constant pressure to increase earnings.

Startup 98
article thumbnail

Bio Roundup: Clinical Shirkers, AMD Worriers, ASH Fallers & More

Xconomy

Its owner Pfizer (NYSE: PFE ) shelved it this week , citing poor Phase 3 data and pricing pressures on the two approved PCSK9 drugs. —Several other biotechs released ASH abstract data, and the net effect was a drop in most stocks. One latecomer, bococizumab, won’t even reach approval. ” ASH THURSDAY.